Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

Launched by SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD · May 28, 2024

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment called ZG006 for patients with advanced small cell lung cancer or neuroendocrine carcinoma, a type of cancer that affects hormone-producing cells. The study has two parts. In the first part, researchers will gradually increase the dose of ZG006 to find out how much of the drug is safe and tolerable for patients. Once this is determined, they will select two doses to use in the second part of the study, which will focus specifically on patients with neuroendocrine carcinoma to see how effective and safe ZG006 is for them.

To be eligible for this trial, participants must be between 18 and 75 years old and able to understand the study and give their consent. They should also be in relatively good health, with a performance status (a measure of how well they can carry out daily activities) of 0 or 1, meaning they are fully active or only slightly limited in their activities. Participants can expect close monitoring throughout the trial to ensure their safety and to gather important information about how well the treatment works. If you or someone you know is considering joining this trial, it’s a great opportunity to contribute to research that may help others with similar conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Fully understand the study and voluntarily sign the informed consent form;
• • Male or female 18\~75 years of age;
• • Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;
• • Life expectancy ≥ 3 months.
• Exclusion Criteria:
• • Participants were deemed unsuitable for participating in the study by the investigator for any reason.

Trial Officials